Rigorously tested and continuously validated in practice, Cytel software is used at thousands of pharmaceutical, biotech, medical device companies, and leading independent research institutes.
Cytel’s cutting-edge trial design and implementation expertise, with a specialty in adaptive trials, is helping sponsor companies of all sizes to increase success rates in clinical development.
Adaptive Dose-Escalation and Trial Prediction in East® v6.3
New dose-escalation designs, gatekeeping procedures for multiple endpoints, and interim analysis trial prediction tools, continue East® software’s twenty year tradition of reliable innovation.
DIA Webinar: Integrating Adaptive Trials and Financial Decision-Making
Cytel CTO, Chairman and Co-Founder Nitin Patel and Pharmagellan’s Frank David reveal how savvy companies are also using adaptive trial designs to help determine drug development funding strategies.
Register for EUGM 2014: East® User Group Meeting
Our annual EUGM begins with East software training on Oct 21. The Oct 22 adaptive trial innovations Open Meeting features guests LJ Wei, Michael Proshan, and Ashwin Gollerkeri.
What Clients Say
Simona Skerjanec, VP Medical Science
The Medicines Company
Steven B. Ketchum, VP Research and Development
Joe Heyes, VP
Early Stage Biostatistics Merck
Dr. Scott Harris, CMO
Dr. Patrice Rioux, VP, CMO
Sylvain Nicolas, Global Head Biostatistics Phase 1 Studies